Status: Open Not Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Daniel (cancer) Le (cancer)
Phone: 346.238.5655
A Phase 2, multicenter, open-label, 2-stage study to assess the safety, tolerability, and efficacy of XERMELO in combination with first-line (1L) therapy (cisplatin [cis] plus gemcitabine [gem]) in patients with unresectable, locally advanced, r ... Read more >
Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Juan Morales Viera
Phone: 786.803.2333
The purpose of this study is to evaluate the efficacy of zolbetuximab plus capecitabine and oxaliplatin (CAPOX) compared with placebo plus CAPOX (as first-line treatment) as measured by Progression Free Survival (PFS). This study will also ev ... Read more >
Status: Open Not Enrolling
Investigator: Maen Abdelrahim
Study Coordinator:
Phone:
The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment. This study will also ... Read more >
Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Jose Cruz
Phone: 713.441.4457
The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement. < ... Read more >
Status: Open Not Enrolling
Investigator: Mahendra Jain
Study Coordinator: Bela Jain
Phone: 281.485.3434
To evaluate whether selonsertib (SEL) can slow the decline in kidney function, reduce the risk of kidney failure, or reduce the risk of death due to kidney disease in subjects with diabetic kidney disease (DKD) ... Read more >
Status: Open Not Enrolling
Investigator: Mahendra Jain
Study Coordinator: Bela Jain
Phone: 281.485.3434
In patients with diabetes and high triglycerides, subjects will be given pemafibrate to help reduce triglycerides level and cardiovascular outcomes. ... Read more >
Status: Enrolling
Investigator: Kirk Heyne
Study Coordinator: Caroline Fitzgerald
Phone: 713.441.3250
The purpose of this study is to investigate nivolumab combined with Debio 1143. The study will focus on subjects with specific solid tumors for whom tumors were previously treated with anti-PD-1/PD-L1 therapy as a single therapy (or when used wi ... Read more >
Status: Enrolling
Investigator: Mark Sultenfuss
Study Coordinator:
Phone:
This research registry studies Yttrium Y 90 resin microspheres in collecting data from patients with liver cancer not capable of being removed by surgery (unresectable) for the radiation-emitting Selective Internal Radiation-Spheres (SIR-spheres ... Read more >
